- Catalogue N°
- 873.100.048 - 1 x 48 Discovery (pre-coated)
873.100.096 - 1 x 96 (pre-coated)
873.100.192 - 2 x 96 (pre-coated)
- Assay Range
- 31.25-500 pg/ml
- 8 pg/ml
- Target species
- Sample Type
- Cell culture supernatant, serum, plasma
- Sample Size
- 50µl / 100µl
- Cross Reaction
- No cross reactivity with GM-CSF, MICB, IL-34, IFNg, IL-29, Galectin-1, Galectin-3, Galectin-8, Galectin-10
- Kit Content
- Diaclone ELISA Kits include pre-coated strip plates, biotinylated secondary antibody, standards, controls (where applicable), buffers, streptavidin-HRP, TMB, stop reagents and a detailed procedure.
Galectins is a family of non-classically secreted, β-galactoside-binding proteins that has recently received considerable attention.
Galectin-9 is a unique member of this family with a 39kDa tandem-repeat type galectin with two carbohydrate-recognition domains. It was first identified as an eosinophil chemoattractant and activation factor and first cloned from tumor tissues of Hodgkin’s disease. Subsequent studies revealed that galectin-9, similar to other galectins, modulates a variety of biological functions including cell aggregation and adhesion, as well as apoptosis of tumor cells. Galectin-9 has recently been shown to have an anti-proliferative effect on cancer cells.
Recent studies have uncovered additional mechanisms by which T cell immunoglobulin mucin-3 (TIM-3), a receptor for galectin-9, negatively regulates T cell responses by promoting CD8+ T cell exhaustion and inducing expansion of myeloid-derived suppressor cells. These mechanisms are involved in tumor growth and escape from immunity. In many solid cancers, the loss of galectin-9 expression is closely associated with metastatic progression, and treatment with recombinant galectin-9 prevents metastatic spread in various preclinical cancer models.
Version 3 - 07.19
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.